Aurinia Pharmaceuticals (AUPH) Other Accumulated Expenses (2019 - 2026)

Aurinia Pharmaceuticals has reported Other Accumulated Expenses for 8 years, with the latest figure at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 48.79% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (up 48.79% YoY), and the FY2025 full-year result was $2.5 million, up 61.99% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $2.5 million, up from $2.5 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $2.6 million in Q3 2023, with the low at $502000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $1.8 million across 5 years, with a median of $2.0 million in 2023.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses sank 88.79% — and 2023, when it soared 294.22%.
• Aurinia Pharmaceuticals' Other Accumulated Expenses stood at $2.0 million in 2022, then climbed by 17.46% to $2.4 million in 2023, then tumbled by 35.89% to $1.5 million in 2024, then soared by 61.99% to $2.5 million in 2025, then gained by 1.69% to $2.5 million in 2026.
• The last three Other Accumulated Expenses figures came in at $2.5 million (Q1 2026), $2.5 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.